Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

380

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

September 30, 2014

Conditions
Atopic Dermatitis
Interventions
DRUG

Dupilumab

DRUG

Placebo

Trial Locations (84)

Unknown

Birmingham

Mobile

Tucson

Bakersfield

San Diego

Santa Monica

Jacksonville

Ormond Beach

Skokie

New Orleans

Andover

Boston

Troy

St Louis

New York

Rochester

Winston-Salem

Portland

Pittsburgh

Johnston

Greer

Nashville

Houston

San Antonio

Seattle

Vancouver (2 Locations)

Winnipeg

Barrie

Hamilton

Markham

Oakville

Peterborough

Richmond Hill

Waterloo

Windsor

Saint-Hyacinthe

Québec

Kutná Hora

Náchod

Prague

Svitavy

Ústí nad Labem

Augsburg

Baden

Berlin

Bonn

Dresden

Dülmen

Frankfurt am Main

Frankfurt/Main, Hessen

Gera

Hamburg

Heidelberg

Kiel

Mahlow

Munich

Münster

Osnabrück

Tübingen

Borsod-Abauj-Zemplen

Budapest

Kaposvár

Szeged

Szolnok

Tolna

Fukuoka

Hokkaido

Saitama

Tokyo, Bunkyo-ku

Tokyo, Chiyoda-ku

Tokyo, Nakano-ku

Tokyo, Nerima-ku

Tokyo, Shibuya-ku

Tokyo, Shinagawa-ku

Tokyo, Shinjuku-ku (2 Locations)

Tokyo, Suginami-ku (2 Locations)

Yokohama

Gdansk (2 Locations)

Katowice

Lodz

Lublin

Poznan

Warsaw (2 Locations)

Wroclaw

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY